Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (U01 AI142756)
U.S. Department of Health & Human Services | NIH | National Human Genome Research Institute (RM1 HG009490)
U.S. Department of Health & Human Services | NIH | National Institute of Biomedical Imaging and Bioengineering (R01 EB022376)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35 GM118062)
Howard Hughes Medical Institute (Liu investigatorship)
Article History
Received: 16 October 2019
Accepted: 27 March 2020
First Online: 22 May 2020
Competing interests
: D.R.L. is a consultant and co-founder of Prime Medicine, Beam Therapeutics, Pairwise Plants, and Editas Medicine, companies that use genome editing. Complete disclosures are available at ExternalRef removed.